The Chronic Kidney Disease Drugs Market provides drugs for early and late stage treatment of chronic kidney disease. Chronic kidney disease drugs helps slow down the progression of kidney damage by controlling blood pressure and reducing protein in urine. Also, these drugs help manage symptoms like anemia, bone disease, potassium level, acidosis, and phosphorus level. Chronic kidney disease affects a large population globally due to risk factors like diabetes, hypertension, obesity, and cardiovascular disease.

The chronic kidney disease drugs market comprises drugs for early and late stage treatment of chronic kidney disease conditions. These include Erythropoiesis-stimulating agents (ESAs), Calcium channel blockers, Angiotensin-converting enzyme (ACE) inhibitors and Angiotensin II receptor antagonists, Beta-blockers, Diuretics (water pills), and Phosphate binders. Chronic kidney disease drugs help manage symptoms and slow down progression of kidney damage.

The global Chronic Kidney Disease Drugs Market is estimated to be valued at US$ 13,220.0 Mn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The chronic kidney disease drugs market is witnessing high growth owing to rising incidences of chronic kidney disease globally. According to the National Kidney Foundation, over 850 million people suffer from chronic kidney disease worldwide. Risk factors like growing geriatric population, increasing prevalence of diabetes and hypertension, genetic predisposition, and obesity are contributing to the rising burden of chronic kidney disease globally. As per estimates, around 90% chronic kidney disease cases are caused due to conditions like diabetes and hypertension. Rising health awareness and availability of chronic kidney disease treatment options are also driving the growth of this market. However, high cost of chronic kidney disease drugs limits their access in low and middle-income countries. Companies are engaged in developing more cost-effective generics and biosimilars to expand reach in such regions.

Porter’s Analysis

Threat of new entrants: The threat of new entrants in chronic kidney disease drugs market is low due to presence of strong intellectual property rights and high capital requirements.

Bargaining power of buyers: The bargaining power of buyers in chronic kidney disease drugs market is moderate as branded drugs have strong intellectual property rights thereby limiting buyer substitutes.

Bargaining power of suppliers: The bargaining power of suppliers in the market is low due to presence of many suppliers and easy availability of raw materials.

Threat of new substitutes: The threat of substitutes is low as chronic kidney disease has limited treatment options.

Competitive rivalry: The competitive rivalry in the market is high due to presence of many global and local players.

SWOT Analysis

Strength: Strong pipeline of drugs, innovative therapeutics and growing research and development activities.

Weakness: High costs associated with drug development and regulations. Complex treatment pathways.

Opportunity: Rising healthcare expenditure, growing geriatric population and increasing prevalence of chronic kidney disease. New market opportunities in emerging countries.

Threats: Price erosion due to patent expiries. Biosimilars entry post patent expiry. Stringent regulatory framework.

Key Takeaways

The global Chronic Kidney Disease Drugs Market is expected to witness high growth, exhibiting CAGR of 4.5% over the forecast period, due to increasing prevalence of diseases like diabetes and hypertension affecting the kidneys.

Regional analysis North America accounted for the largest share in the global Chronic Kidney Disease Drugs Market in 2023 and is projected to dominate the market over the forecast period. This is attributed to the growing geriatric population, availability of advanced healthcare facilities and strong presence of leading players in the region.

Key players operating in the Chronic Kidney Disease Drugs market are Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Te